IP Library Granted Patent US 7,892,826
Granted Patent B2
US 7,892,826 · App. 11/501,559 · Granted Feb 22, 2011

Human cell clones having an endogeneous urotensin II receptor

Assignee: Janssen Pharmaceutica N.V.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,892,826
App. No.
11/501,559
Granted
Feb 22, 2011
Kind
B2
Abstract

Human cell clones with increased specific binding to urotensin II have been sub-cloned from SJRH30 (ATCC® Number: CRL-2061™). These cell clones have been used for functional analyses of the biological activity of an endogeneous urotensin II receptor, as well as for identifying compounds that regulate the biological activity of an Urotensin II receptor.

Claims (10)

1. A human cell clone that is a sub-clone of SJRH30 (ATCC® Number: CRL-2061™), having at least about 50% more endogeneous urotensin II binding sites cell −1 than those of the parental SJRH30.

2. A cell culture comprising cells of a human cell clone that is a sub-clone of SJRH30 (ATCC® Number: CRL-2061™), having at least about 50% more endogeneous urotensin II binding sites cell −1 than those of the parental SJRH30.

3. A human cell clone having at least about 100% more endogeneous urotensin II binding sites cell −1 than those of the parental SJRH30.

4. The human cell clone of claim 3 that is the 4G5 cell clone (ATCC® Number: PTA-7747).

5. The human cell clone of claim 3 that is the 10A7 cell clone (ATCC® Number: PTA-7748).

6. The human cell clone of claim 3 that is the 6D9 cell clone (ATCC® Number: PTA-7749).

7. A cell culture comprising cells of a human cell clone that is a sub-clone of SJRH30 (ATCC® Number: CRL-2061™), having at least about 100% more endogeneous urotensin II binding sites cell −1 than those of the parental SJRH30.

8. The cell culture of claim 7 comprising cells of 4G5 cell clone (ATCC® Number: PTA-7747).

9. The cell culture of claim 7 comprising cells of 10A7 cell clone (ATCC® Number: PTA-7748).

10. The cell culture of claim 7 comprising cells of 6D9 cell clone (ATCC® Number: PTA-7749).

Assignments (3)
MERGER Recorded Jan 13, 2011
From: ORTHO-MCNEIL PHARMACEUTICAL, INC.; JANSSEN PHARMACEUTICA INC.
To: ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.
Reel/Frame 025628/0554 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2011
From: ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.
To: JANSSEN PHARMACEUTICA N.V.
Reel/Frame 025628/0590 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2006
From: MINOR, LISA; QI, JENSON; WANG, YUANPING
To: ORTHO-MCNEIL PHARMACEUTICAL, INC.
Reel/Frame 018334/0109 →
Continuity (2)
Provisional Application 60708221 · Aug 15, 2005
Related Publication 20070082368A1 · Apr 12, 2007